1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response - Informed Consent Form
   Response - Clinical Study Report
   Response -  Analytic Code
   
   
3. Who will be able to view these files?
   Response - Researchers who provide a methodologically sound proposal.
   


4. For what types of analyses will this data be available?
   Response - To achieve aims in the approved proposal.
   


5. By what mechanism will data be made available?
   Response - Proposals should be directed to [samanvitha.t-hmcpune@bvp.edu.in].
   


6. For how long will this data be available start date provided 22-09-2025 and end date provided 22-03-2027?
   Response - Beginning 3 months and ending 5 years following article publication.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

Diabetic retinopathy (DR) represents a significant global health challenge, especially given the rising prevalence of diabetes mellitus worldwide. In recent years, there have been remarkable strides in the diagnosis, technological advancements, and treatment options for DR, which have significantly changed the way we approach and manage the condition. Key developments such as the widespread availability of optical coherence tomography (OCT) for imaging, as well as the introduction of anti-vascular endothelial growth factor (VEGF) therapies, have dramatically improved both the early detection and treatment of DR. These advancements have paved the way for better outcomes for patients. However, the field continues to evolve, with ongoing research and innovations offering promising new solutions for further improving the management and treatment of diabetic retinopathy. Homoeopathy has the potential to treat various ophthalmic conditions quickly, effectively, and safely, with minimal risk of recurrence.

AIM: to test the efficacy of individualized treatment in homoeopathy as an adjuvant therapy to standard medical care in the management of non-proliferative diabetic retinopathy.

MATERIALS AND METHODS: A prospective, single blind, randomized controlled trial with a 6-month follow-up period, will be conducted at BHARATI VIDYAPEETH  (Deemed to be University) HOMOEOPATHIC MEDICAL COLLEGE & HOMOEOPATHIC HOSPITAL OPD, Pune. Thirty participants fulfilling the inclusion criteria will be randomized into 2 groups- group A will receive Individualized homoeopathic treatment along with standard medical care while group B will receive placebo .The cases will be analyzed and evaluated for the condition over a duration of 6 months with monthly follow ups. The ophthalmologist and homoeopathic expert will follow up concurrently. Frequency for fundoscopy follow up will be determined by ophthalmologist on basis of symptoms of the patient. At the end of the study, the patient is again evaluated on the parameters of baseline assessment and the results are concluded after the analysis with appropriate statistical tools.

T